skip to Main Content

Dr. Hochster on SWOG S1513 Results in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discussed results from the SWOG S1513 study, which examined the use of second-line modified FOLFIRI with the PARP inhibitor ABT-888 (Veliparib) versus FOLFIRI alone in metastatic pancreatic cancer.

Watch here . . .

Back To Top